Neurocritical Care News

The FDA has issued a complete response letter to Ipsen for its new drug application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation in people with fibrodysplasia ossificans progressiva.

KGK Sciences Inc. received a no objection letter from Health Canada to proceed with a phase 2a clinical trial evaluating the use of psilocybin for fragile X syndrome, the leading genetic cause of autism spectrum disorder.

Traumatic brain injury, PTSD and the apolipoprotein E4 gene showed strong associations with Alzheimer’s disease and related dementias, researchers reported in Alzheimer’s & Dementia.

On Dec. 8, Grammy award-winning artist Celine Dion announced that she would be rescheduling her 2023 tour dates after being diagnosed with stiff-person syndrome, a progressive neurological disorder.

The consumption of walnuts was shown to reduce academic stress and bolster mental health among university students, especially women, researchers reported in Nutrients.

Psychological distress symptoms were significantly associated with increased risk for all-cause dementia, researchers reported in JAMA Network Open.

Avidity Biosciences Inc. announced positive data from a phase 1/2 trial, which successfully delivered RNA into muscle for the first time in a study that aimed to treat patients with myotonic dystrophy, the company said in a press release.

Use of a genetic risk test for patients considering immunosuppressive therapies associated with development of progressive multifocal leukoencephalopathy may help reduce incidence of disease, researchers reported in Frontiers in Neurology.

An estimated 55.8 million patients presented to U.S. emergency departments from 2016 to 2019 with a neurological complaint as the primary reason for their visit, researchers reported in JAMA Neurology.

Biotechnology startup company Camellix has announced the discovery of a green tea-derived polyphenol molecule that may be effective in treating neurological symptoms associated with long COVID, including loss of smell and brain fog.